Studies evaluating thrombophilia as risk factor for cerebral vein thrombosis
| First author (reference) . | Patients/controls . | Risk factors analyzed . | Main results . |
|---|---|---|---|
| de Bruijn (7) | 40/2248 | FVL, OC. AT, PC, PS | OC associated with 13-fold increased risk; controls not tested for thrombophilia |
| Martinelli (8,9) | 121/242 | FVL, PT, OC, HHcy, AT, PC, PS APA | FVL associated with 5-fold, PT with 10-fold, HHcy with 4-fold and OC with 6-fold increased risk |
| Gadelha (10) | 26/217 | FVL, PT, OC | PT associated with 21-fold, OC with 8-fold increased risk |
| Rodrigues (11) | 42/134 | FVL, PT, OC | PT associated with 27-fold, OC with 10.5-fold increased risk |
| Bombeli (12) | 51/120 | FVL, PT, AT, PC, PS | Any inherited thrombophilia associated with 2.5-fold increased risk |
| Boncoraglio (13) | 28/100 | FVL, PT, HHcy | HHcy associated with 4-fold increased risk |
| Ventura (14) | 30/40 | FVL, PT, HHcy | PT associated with 16-fold, HHcy with 7-fold increased risk |
| Bugnicourt (15) | 25/64 | FVIII, VWF | FVIII and VWF plasma levels significantly higher in CVT |
| Voetsch (16) | 23/123 | H2 aplotype in the GPx-3 gene promoter | H2 haplotype in the GPx-3 gene promoter associated with 11-fold increased risk |
| Lichy (17) | 77/203 | FVL, PT, TAFI G-438A, PZ Intron FG79A | PT associated with 5-fold, FVL with 2-fold increased risk |
| Libourel (18) | 63/209 | FVL, PT, AT, PC, PS, FVIII, FIX, FXI, HHcy | The majority of CVT patients had single or multiple thrombophilic abnormalities |
| First author (reference) . | Patients/controls . | Risk factors analyzed . | Main results . |
|---|---|---|---|
| de Bruijn (7) | 40/2248 | FVL, OC. AT, PC, PS | OC associated with 13-fold increased risk; controls not tested for thrombophilia |
| Martinelli (8,9) | 121/242 | FVL, PT, OC, HHcy, AT, PC, PS APA | FVL associated with 5-fold, PT with 10-fold, HHcy with 4-fold and OC with 6-fold increased risk |
| Gadelha (10) | 26/217 | FVL, PT, OC | PT associated with 21-fold, OC with 8-fold increased risk |
| Rodrigues (11) | 42/134 | FVL, PT, OC | PT associated with 27-fold, OC with 10.5-fold increased risk |
| Bombeli (12) | 51/120 | FVL, PT, AT, PC, PS | Any inherited thrombophilia associated with 2.5-fold increased risk |
| Boncoraglio (13) | 28/100 | FVL, PT, HHcy | HHcy associated with 4-fold increased risk |
| Ventura (14) | 30/40 | FVL, PT, HHcy | PT associated with 16-fold, HHcy with 7-fold increased risk |
| Bugnicourt (15) | 25/64 | FVIII, VWF | FVIII and VWF plasma levels significantly higher in CVT |
| Voetsch (16) | 23/123 | H2 aplotype in the GPx-3 gene promoter | H2 haplotype in the GPx-3 gene promoter associated with 11-fold increased risk |
| Lichy (17) | 77/203 | FVL, PT, TAFI G-438A, PZ Intron FG79A | PT associated with 5-fold, FVL with 2-fold increased risk |
| Libourel (18) | 63/209 | FVL, PT, AT, PC, PS, FVIII, FIX, FXI, HHcy | The majority of CVT patients had single or multiple thrombophilic abnormalities |
FVL indicates factor V Leiden; PT, prothrombin G20210A mutation; PC, protein C deficiency; PS, protein S deficiency; AT, antithrombin deficiency; APA, antiphospholipid antibodies; HHcy, hyperhomocysteinemia; OC, oral contraceptive; CVT, cerebral vein thrombosis; GPx-3, glutathione peroxidase; TAFI, thrombin activatable fibrinolysis inhibitor; PZ, protein Z; FVIII, factor VIII; VWF, von Willebrand factor; CVT, cerebral venous thrombosis; FIX, factor IX; and FXI, factor XI.